Search

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Thursday, February 27, 2020 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Sergio Giralt, MD Sergio Giralt Is Named Deputy Division Head of the Division of Hematologic Malignancies Sergio Giralt, MD , Chief of the Adult Bone Marrow Transplant Service (BMT

Once a patient, Jillian is now a breast cancer care coordinator. She shares a love story, a viral video and a special connection to the people of MSK Monmouth.

… Saturday, July 1, 2023 By Katie Sobolik There’s something patients don’t know about Jillian Allegretti as she helps them manage their appointments at MSK Monmouth , one of several Memorial Sloan Kettering Cancer Center (MSK) regional locations . Behind her warm smile and calm professionalism lies a shared

Memorial Sloan Kettering Cancer Center (MSK) issued the following statement regarding its first quarter 2023 financial results today.

… Monday, May 15, 2023 Memorial Sloan Kettering Cancer Center (MSK) issued the following statement regarding its first quarter 2023 financial results today: MSK’s financial performance in the first quarter of 2023 instills confidence that by following the sound financial strategy we have put in place we

These special awards are presented to researchers and global oncology leaders who have reshaped cancer care around the world and are among the highest honors bestowed by ASCO.

… Tuesday, March 29, 2022 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Fumiko Chino, MD; Craig B. Thompson, MD; and Jedd D. Wolchok, MD, PhD, FASCO, have been honored by the American Society of Clinical Oncology (ASCO) and Conquer Cancer, the ASCO Foundation, with three prestigious

CyberKnife is a brand name for one of several available stereotactic radiosurgery devices that deliver radiation with linear accelerators. MSK uses a similar device, made by a company called Varian, that destroys tumors with extremely precise, very intense doses of radiation.

… Monday, February 24, 2014 Summary CyberKnife is a brand name. It refers to a stereotactic body radiation therapy device that delivers radiation using advanced imaging technology. MSK uses similar technology as part of an approach called MSK Precise TM . This method destroys tumors with very intense doses

Cancers with certain mutations are vulnerable to ferroptosis, a form of iron-dependent cell death.

… Monday, November 23, 2020 Summary Genetic mutations that give cancers a metabolic boost may also leave them vulnerable to drugs that promote a particular form of cell death, Sloan Kettering Institute researchers have found. If there is a silver lining in cancer’s chaotic biology, it’s that the same traits

Learn about some of the exciting research that MSK doctors and scientists presented at the 2025 Annual Meeting of the American Society for Radiation Oncology.

… Wednesday, October 1, 2025 Memorial Sloan Kettering Cancer Center (MSK) presented new research on a range of important topics at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO), held September 27 to October 1 in San Francisco. The presentations included two clinical trials

Get an inside look into the life of a student from the Gerstner Sloan Kettering (GSK) Graduate School of Biomedical Sciences.

… Tuesday, November 23, 2021 As a student at the Gerstner Sloan Kettering (GSK) Graduate School of Biomedical Sciences, you will join the laboratory of one of more than 130 scientists from Memorial Sloan Kettering Cancer Center with expertise in cancer biology, genomics, immunology, structural biology,

Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.

… Wednesday, August 19, 2015 Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer

Learn why MSK researchers developed MACHETE, a new CRISPR-based technique to study large-scale genetic deletions efficiently in laboratory models.

… Monday, November 7, 2022 Highlights MACHETE is a new CRISPR-based technique to study large-scale genetic deletions efficiently in laboratory models. Using MACHETE, researchers found that a prominent deletion often eliminates a cluster of interferon genes — leading to poorer outcomes in mouse models of